clinical data

Clinical data for the T-SPOT.TB test

Peer reviewed publications continue to add to the body of evidence supporting the clinical utility of the T-SPOT.TB test across patient populations. Below are an assortment of relevant publications to support your clinical decisions.

T-SPOT.TB Interferon-γ Release Assay Performance in Healthcare Worker Screening at Nineteen U.S. Hospitals

King, TC, Upfa M, et al. T-SPOT.TB Interferon-γ Release Assay Performance in Healthcare Worker Screening at Nineteen U.S. Hospitals. American Journal of Respiratory and Critical Care Medicine, Vol. 192, No. 3 (2015), pp. 367-373. doi: 10.1164/rccm.201501 0199OC.

This landmark study of over 42,000 serial tests from 19 geographically diverse US hospitals demonstrates the performance of the T-SPOT.TB test. 

Key findings in this paper include:

  • 98.9% concordance rate
  • 0.8% mean conversion rate (negative result converting to a positive result)
  • 17.6% mean reversion rate (positive result converting to a negative result)
  • T-SPOT.TB results are strongly correlated to known tuberculosis (TB) risk factors
  • This study demonstrated the T-SPOT.TB test is a reliable tool for healthcare worker screening

Screening health care workers with interferon-γ release assay versus tuberculin skin test: Impact on costs and adherence to testing (the SWITCH study)

Bernacki E, Humphrey F, Sneed L, Tao X, Wrighton-Smith P. “Screening health care workers with interferon-γ release assay versus tuberculin skin test: impact on costs and adherence to testing (the SWITCH study).” J Occup Environ Med. 2012 Jul;54(7):806-15. doi: 10.1097/JOM.0b013e318254620f.

This landmark study is the first-of-its-kind to analyze the actual cost of a TB surveillance program using the tuberculin skin test (TST) or the T-SPOT.TB test by obtaining direct measurements of all program components.

Key findings in this paper include:

  • The study exposes the false economics of the TST, demonstrating that it actually costs $73.20 per test to perform when accounting for all components of a TST screening program
  • A test price of $54.83 or lower for the T-SPOT.TB test is more cost-effective than the TST
  • T-SPOT.TB compliance was 99%; increasing the TST compliance to 98.5% would cost an additional $20.59 per employee

Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease

Clark SA, Martin SL, Pozniak A, et al. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol. 2007;150(2):238–244. doi:10.1111/j.1365-2249.2007.03477.x

This study evaluated whether it is possible to detect TB antigen-specific immune responses using ELISPOT technology in HIV-1 patients – a hard to screen patient population.

A key finding in this study includes:

  • The sensitivity of the T-SPOT.TB test remains high in HIV patients, regardless of CD4 T cell count

Utility of the T-SPOT.TB test’s borderline category to increase test resolution for results around the cut-off point

Rego, K, Pereira K, et al. Utility of the T-SPOT.TB test’s borderline category to increase test resolution for results around the cut-off point. Tuberculosis. 2018;108:178-185. doi.org/10.1016/j.tube.2017.12.005.

This paper analyzed over 645,000 T-SPOT.TB tests to examine the utility of the borderline zone.

Key findings from this study include:

  • Patients who received borderline results could have been inappropriately classified if using a single cut-off point test with no borderline category
  • The FDA-approved T-SPOT.TB test borderline zone provided increased test resolution around the test cut-off point
  • Invalid rate of 0.6% in a study of > 645,000 tests

Diagnostic performance of whole-blood interferon-γ assay and enzyme-linked immunospot assay for active tuberculosis

Lai CC, Tan CK,et al. Diagnostic performance of whole-blood interferon-γ assay and enzyme-linked immunospot assay for active tuberculosis. J Microbiol Immunol Infect. 2011 Oct;44(5):406-7. doi: 10.1016/j.jmii.2011.07.002. Epub 2011 Sep 8.

This study compared the diagnostic performance of two interferon-gamma release assays in patients with suspected active TB.

Key findings from this study include:

  • The T-SPOT.TB test had less false negative results, especially in immunocompromised patients, compared to the other commercially available IGRA
  • The T-SPOT.TB test had a higher sensitivity than the other commercially available IGRA

Tuberculosis Screening of New Hospital Employees Compliance, Clearance to Work Time, and Cost Using Tuberculin Skin Test and Interferon-Gamma Release Assays

Foster-Chang, SA DNP, APRN-BC, COHN-S; Manning, ML PhD, CRNP, CIC, FAAN; et al. Tuberculosis Screening of New Hospital Employees Compliance, Clearance to Work Time, and Cost Using Tuberculin Skin Test and Interferon-Gamma Release Assays. Workplace Health & Safety. 2014 Sep:62(11): 460-467 doi.org/10.3928/21650799-20140902-02

This study examines the administrative, logistic and technical ease of use of an interferon-gamma release assay (IGRA) compared to the tuberculin skin test (TST) when screening new hired healthcare personnel.

Key findings in this study include:

  • The average time to clear new employees to start work decreased from 13.18 days to 5.91 days when the institution used an IGRA instead of the TST
  • TB screening costs were reduced by 38% – 40% when institutions utilized  an IGRA
  • Selection of the most suitable TB test should be based on purpose, setting, effectiveness and cost

T-SPOT.TB package insert

The T-SPOT.TB test is an in vitro diagnostic test for the detection of effector T cells that respond to stimulation by Mycobacterium tuberculosis antigens ESAT-6 and CFP10 by capturing interferon-gamma (IFN-γ) in the vicinity of T cells in human whole blood collected in sodium citrate or sodium or lithium heparin. It is intended for use as an aid in the diagnosis of M. tuberculosis infection.

Learn more about the
T-SPOT.TB test

Contact Us